ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
4 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
5 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Proposed issue of securities - PAA
|
|
ma420
|
15 |
3.0K |
6 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
15
|
3.0K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
ma420
|
159 |
37K |
3 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
159
|
37K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Proposed issue of securities - PAA
|
|
ma420
|
15 |
3.0K |
3 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
15
|
3.0K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Proposed issue of securities - PAA
|
|
ma420
|
15 |
3.0K |
17 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
15
|
3.0K
|
17
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
11 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
11
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
11 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
11
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
624 |
199K |
12 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
624
|
199K
|
12
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
624 |
199K |
9 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
624
|
199K
|
9
|
|
ASX - By Stock
|
COV |
Re:
Ann: Restricted securities to be released from escrow
|
|
ma420
|
3 |
906 |
1 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
3
|
906
|
1
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
9 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
13 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
13
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
624 |
199K |
2 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
624
|
199K
|
2
|
|
ASX - By Stock
|
BOT |
Re:
Ann: FDA Approves Sofdra
|
|
ma420
|
484 |
157K |
4 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
484
|
157K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
ma420
|
56 |
15K |
12 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
56
|
15K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
ma420
|
41 |
13K |
18 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
41
|
13K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
ma420
|
159 |
37K |
12 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
37K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
ma420
|
159 |
37K |
20 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
37K
|
20
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
ma420
|
80 |
24K |
6 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
24K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix to present at Melbourne Twilight Investor Briefing
|
|
ma420
|
67 |
24K |
5 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
67
|
24K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
10 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
213
|
89K
|
10
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
103K |
7 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
230
|
103K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
103K |
22 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
230
|
103K
|
22
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
103K |
20 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
230
|
103K
|
20
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
2 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
213
|
89K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
2 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
213
|
89K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
103K |
4 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
230
|
103K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
103K |
16 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
230
|
103K
|
16
|
|
ASX - By Stock
|
DXB |
Re:
Banter and general comments
|
|
ma420
|
20 |
6.5K |
1 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
20
|
6.5K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
3 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
213
|
89K
|
3
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
174 |
81K |
15 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
174
|
81K
|
15
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
3.8M |
12 |
14/06/24 |
14/06/24 |
General
|
11K
|
3.8M
|
12
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
3.8M |
2 |
14/06/24 |
14/06/24 |
General
|
11K
|
3.8M
|
2
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
174 |
81K |
21 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
174
|
81K
|
21
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
1.7K |
615K |
8 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
1.7K
|
615K
|
8
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
3.8M |
25 |
14/06/24 |
14/06/24 |
General
|
11K
|
3.8M
|
25
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
5 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
213
|
89K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity Confirms No Supply Disruptions for Clinical Trials
|
|
ma420
|
11 |
4.4K |
1 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
11
|
4.4K
|
1
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
174 |
81K |
18 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
174
|
81K
|
18
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
18 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
213
|
89K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
1.7K |
615K |
2 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
1.7K
|
615K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
1.7K |
615K |
0 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
1.7K
|
615K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
34K |
0 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
110
|
34K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
34K |
1 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
110
|
34K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
34K |
0 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
110
|
34K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
ma420
|
82 |
23K |
1 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
23K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
1.7K |
615K |
2 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
1.7K
|
615K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Application for quotation of securities - RAC
|
|
ma420
|
1 |
774 |
9 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
1
|
774
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
ma420
|
82 |
23K |
14 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
23K
|
14
|
|